Optimal management of elderly patients with myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N. Engl. J. Med. 364, 1046–1060 (2011)
   PubMed Web of Science ®Google Scholar
• Howlade N, Noone A, Krapcho M et al. SEER Cancer Statistics Review (1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site (1012).
   Google Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23, 3–9 (1009).
   Google Scholar
• Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N. Engl. J. Med. 365, 474–475 (1011).
   Google Scholar
• Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 40, 373–383 (1987).
   PubMedGoogle Scholar
• Palumbo A, Bringhen S, Ludwig H et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118, 4519–4529 (2011).
   PubMed Web of Science ®Google Scholar
• Fayers PM, Palumbo A, Hulin C et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118, 1239–1247 (2011).
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906–917 (2008).
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23, 1337–1341 (2009).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679–686 (2010).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29–37 (2010).
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BGM et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412–3420 (2005).
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Kyle R, Fermand J-P et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117, 4701–4705 (2011).
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Durie BGM, Cavo M et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 27(3), 711–717 (2012).
   PubMedGoogle Scholar
• Ross FM, Avet-Loiseau H, Ameye G et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97, 1272–1277 (2012).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 87, 78–88 (2012).
   PubMed Web of Science ®Google Scholar
• Snozek CLH, Katzmann JA, Kyle RA et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 22, 1933–1937 (2008).
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Blade J, Mateos M-V et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118, 529–534 (2011).
   PubMed Web of Science ®Google Scholar
• Gay F, Larocca A, Wijermans P et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117, 3025–3031 (2011).
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Crowley J, Hoering A et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 27, 226–232 (2013).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26, 149–157 (2012).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104, 3052–3057 (2004).
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370, 1209–1218 (2007).
   PubMed Web of Science ®Google Scholar
• Straka C, Schafer-Eckart K, Bassermann F et al. Prospective randomized trial of len/dex induction followed by tandem MEL140 with autologous blood stem cell transplantation and len maintenance versus continued therapy with len/dex in myeloma patients age 60–75 years: protocol–defined safety analysis after 100 patients. ASH Annu. Meet. Abstr. 120, 2012 (2012).
   Google Scholar
• Palumbo A, Gay F, Falco P et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J. Clin. Oncol. 28, 800–807 (2010).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Hajek R, Tóthová E et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113, 3435–3442 (2009).
   PubMed Web of Science ®Google Scholar
• Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J. Clin. Oncol. 27, 3664–3670 (2009).
   PubMed Web of Science ®Google Scholar
• Beksac M, Haznedar R, Firatli-Tuglular T et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur. J. Haematol. 86, 16–22 (2011).
   PubMed Web of Science ®Google Scholar
• Wijermans P, Schaafsma M, Termorshuizen F et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J. Clin. Oncol. 28, 3160–3166 (2010).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825–831 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112, 3107–3114 (2008).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Waage A, Hulin C et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica 98, 87–94 (2013).
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118, 1231–1238 (2011).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 366, 1759–1769 (2012).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lacy MQ, Hayman SR et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am. J. Hematol. 86, 640–645 (2011).
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J. Clin. Oncol. 28, 2259–2266 (2010).
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Flinn IW, Rifkin R et al. Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study. ASH Annu. Meet. Abstr. 118, 478 (2011).
   Google Scholar
• Mateos M-V, Oriol A, Martínez-López J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11, 934–941 (2010).
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Oriol A, Martínez-López J et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120, 2581–2588 (2012).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 28, 5101–5109 (2010).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D et al. Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan-prednisone (vmp) in newly diagnosed multiple myeloma patients. ASH Annu. Meet. Abstr. 120, 200 (2012).
   Google Scholar
• Kumar S, Flinn I, Richardson PG et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119, 4375–4382 (2012).
   PubMed Web of Science ®Google Scholar
• Falco P, Cavallo F, Larocca A et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia 27(3), 695–701 (2013).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516–2520 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson KC, Kyle RA, Rajkumar SV et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 22, 231–239 (2008).
   PubMed Web of Science ®Google Scholar
• Kastritis E, Palumbo A, Dimopoulos MA. Treatment of relapsed/refractory multiple myeloma. Semin. Hematol. 46, 143–157 (2009).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487–2498 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110, 3557–3560 (2007).
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133–2142 (2007).
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120, 2817–2825 (2012).
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Siegel DS, Martin T et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) (Epub ahead of print).
   PubMedGoogle Scholar
• Vij R, Wang M, Kaufman JL et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119, 5661–5670 (2012).
   PubMed Web of Science ®Google Scholar
• Bensinger W, Wang M, Orlowski RZ et al. Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM). J. Clin. Oncol. 28(15), 8029 (2010).
   Web of Science ®Google Scholar
• Lacy MQ, Kumar SK, LaPlant BR et al. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. ASH Annu. Meet. Abstr. 120, 201 (2012).
   Google Scholar
• Dimopoulos MA, Lacy MQ, Moreau P et al. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: A Phase 3, multicenter, randomized, open-label study. ASH Annu. Meet. Abstr. 120, LBA–6 (2012).
   Google Scholar
• Larocca A, Montefusco V, Oliva S. Pomalidomide cyclophosphamide prednisone is act lenalidomide relapsedrefractory mult myeloma. Abstr No O-5 IMW Clin Lymphoma Myeloma Leuk Meet Abstr (2013).
   Google Scholar
• Mark TM, Boyer A, Rossi AC et al. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. ASH Annu. Meet. Abstr. 120, 77 (2012).
   Google Scholar